~~<i id='8E6CA5F0A7'><strike id='8E6CA5F0A7'><tt id='8E6CA5F0A7'><pre id='8E6CA5F0A7'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

Wikipedia

author：explore 2025-09-05 11:14:28 - browse：7

Alkermes shareholders voted Thursday to re-elect all of the drugmaker’s current directors, ending an acrimonious proxy fight with hedge fund Sarissa Capital Management, which had sought to seat three directors on the board.

At the company’s annual meeting, shareholders voted in favor of Alkermes’ proposal to retain all seven of the director nominees to the 11-person board.

The outcome is a setback for Sarissa, which owns 8.5% of Alkermes and is run by activist investor Alex Denner. Sarissa has accused Alkermes executives of mismanaging the business and destroying shareholder value.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Why the drug industry's warnings on the IRA's impact fall short

explore

hotspot

leisure time

focus

hotspot

FDA'sPeterMarksJIMLOSCALZO/POOL/AFPviaGettyImagesWASHINGTON—TheFoodandDrugAdministrationneedsdozensm

WSS

Radiology is caught between AI's potential and concern for patients

Eli Lilly CEO gives to Mike Pence presidential super PAC

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Teach medical students about patients with intellectual disabilities

Americans' trust in science, scientist continues decline: Report

Pharma patents targeted by Biden in move to slash drug prices

hotspot

Wikipedia

explore

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

What PEPFAR has meant on the ground in Ukraine

Affirmative action in medical school literally saved lives

David Liu startup to focus on CRISPR delivery

Alkermes shareholders re

Patients, doctors press FTC to beef up hospital merger scrutiny

The high cost of giving birth even with insurance

The unintended consequences of overturning Roe v. Wade

Walensky prepares to leave CDC — and Congress — behind

Patients, doctors press FTC to beef up hospital merger scrutiny

hotspot

Congenital heart disease patients face new threat of heart failure

Neurocrine congenital adrenal hyperplasia trial succeeds

Patients, doctors press FTC to beef up hospital merger scrutiny

The woman behind the Dana Farber

Midwives could help bridge maternal health disparities in the U.S.

STAT letters to the editor on burnt

hotspot

leisure time

focus

hotspot